http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
-
TME Pharma Provides Results of First Exercise of Warrants Z
-
TME Pharma Announces FDA Clearance of Investigational New Drug (IND) Application for NOX-A12 Phase 2 Trial in Brain Cancer
-
TME Pharma Provides Results of Final Exercise of Warrants Y: Additional €854K Raised and Extension of Cash Runway From May Into July 2024
-
TME Pharma Announces the End of the Convertible Debt Program With the Successful €1.48 Million Financing Intended for Buyback of All Outstanding Convertible Debt
-
TME Pharma Announces Final Median Overall Survival Data Reaching 19.9 Months for NOX-A12 Combination Regimen in GLORIA Brain Cancer Trial and Survival Rate 10-Fold Greater Than Standard of Care
-
TME Pharma N.V.: Half-yearly Report on the Liquidity Contract With Invest Securities
-
TME Pharma Provides Update on Number of Outstanding Shares and Warrants Following First Warrant Y Exercise Period
-
TME Pharma Announces Successful Advice Meeting With US Food and Drug Administration on NOX-A12 Development in Brain Cancer
-
TME Pharma Announces Further Improvement in Median Overall Survival at 19 Months Follow-up in GLORIA Brain Cancer Trial
-
TME Pharma Announces Results of Successful Capital Increase With Preferential Subscription Rights for €2.7 Million
-
TME Pharma Announces the Initiation of the Listing of Preferential Subscription Rights for Fully Guaranteed €2.7 Million Capital Increase
-
TME Pharma Announces Additional Data From NOX-A12 Combination Regimen in Brain Cancer Presented at SNO 2023 Annual Meeting
-
TME Pharma Reports H1 2023 Financial Results and Provides Business Update
-
TME Pharma Announces Further Improvement in Overall Survival at 18 Months to 67% for NOX-A12 Combination Regimen in Brain Cancer
-
TME Pharma Reports on End of Six-month Lock-up Period of Shares and Convertible Bonds Following the April 2023 Transaction
-
TME Pharma Announces Publication of ESMO Congress 2023 Abstract on the Ongoing NOX-A12 GLORIA Phase 1/2 Trial in Glioblastoma
-
TME Pharma Provides Positive Update on 18-Month Survival for NOX-A12 Combination Regimen in Brain Cancer and Provides Strategic Update Including Decision to Engage with US FDA
-
TME Pharma Announces Selection of Two Clinical Abstracts on the Ongoing NOX-A12 GLORIA Phase 1/2 Trial in Glioblastoma for Presentation at ESMO 2023 Congress and SNO 2023 Annual Meeting
-
TME Pharma N.V. : NOX-A12 Combination Regimen With Bevacizumab: 17-Month Survival Rate Exceeds All Relevant Competitor Treatments Against Most Severe Form of Adult Brain Cancer
-
TME Pharma N.V.: Half-yearly Report on the Liquidity Contract With Invest Securities
-
TME Pharma Provides Positive Data Update on Best Response to Therapy With First Complete Response in GLORIA Trial in Glioblastoma, Bringing 50% of Patients in Expansion Arm to Complete or Near-Complet
-
TME Pharma Announces Positive 15-month Survival Data From GLORIA Expansion Arm Evaluating NOX-A12 in Combination With Radiotherapy and Bevacizumab in Glioblastoma
-
TME Pharma Receives Investigational New Drug (IND) Approval for NOX-A12 From the US FDA
-
TME Pharma Announces Convocation of the 2023 Annual General Meeting of Shareholders
-
TME Pharma Announces Publication of ASCO 2023 Abstract Disclosing New Biomarker Data From NOX-A12 GLORIA Phase 1/2 Trial in Glioblastoma
-
TME Pharma Provides Positive Clinical Update and 14-month Survival Data From GLORIA Expansion Arm Evaluating NOX-A12 in Combination With Radiotherapy and Bevacizumab in Glioblastoma
-
TME Pharma Announces New Data From NOX-A12 GLORIA Phase 1/2 Study in Glioblastoma to Be Presented at ASCO Annual Meeting in June 2023
-
CORRECTING and REPLACING: TME Pharma Publishes Audited Annual Report 2022
-
TME Pharma Publishes Audited Annual Report 2022
-
TME Pharma Announces Successful €2 Million Financing and the End of the Convertible Bond Program With a Lock-Up of New Shares and Lock-Up of Bond Conversions Extending Financial Runway Into December
-
TME Pharma Publishes Unaudited Financial Results for Fiscal Year 2022
-
TME Pharma Announces Temporary Suspension of Liquidity Contract With Invest Securities
-
TME Pharma Announces 83% of Glioblastoma Patients Still Alive After 12 Months on Study (Median) in GLORIA Expansion Arm Evaluating NOX-A12 in Combination With Radiotherapy and Bevacizumab
-
TME Pharma CEO Message
-
TME Pharma Announces Results of the Extraordinary General Meeting of Shareholders
-
TME Pharma Provides Clinical Update on the Gloria Expansion Arm Testing NOX-A12 in Combination With Radiotherapy and Bevacizumab in Patients With Glioblastoma
-
TME Pharma: Half-yearly Report on the Liquidity Contract With Invest Securities
-
TME Pharma Announces Convocation of an Extraordinary General Meeting of Shareholders
-
TME Pharma Announces the Resignation of Its Chief Financial Officer Bryan Jennings
-
Positive Updated Interim Results from NOX-A12 GLORIA Phase 1/2 in Brain Cancer Presented at the Society for Neuro-oncology 2022 Annual Meeting
-
TME Pharma to Host Key Opinion Leader Webinar
-
TME Pharma Announces Publication of Abstract Disclosing Positive Interim Results From Bevacizumab Expansion Arm of NOX‑A12 GLORIA Phase 1/2 Brain Cancer Clinical Trial
-
TME Pharma Reports H1 2022 Financial Results and Provides Business Update
-
TME Pharma Announces Upcoming Presentation at the Society for Neuro-Oncology Annual Meeting 2022
-
TME Pharma N.V.: Safety Confirmed of NOX-A12 and Pembrolizumab Combination in GLORIA Phase 1/2 Brain Cancer Study
-
TME Pharma Announces Enrollment of First Patient in Pembrolizumab Expansion Arm of NOX-A12 GLORIA Phase 1/2 Brain Cancer Clinical Trial
-
TME Pharma Announces Completion of Share Consolidation
